-1753896006195.webp&w=3840&q=75)
2025 NOSCM | Genomics in Treatment Decision for De Novo Acute Myeloid Leukemia
0% Complete
Course Overview
Dr. Fernandez discussed de novo AML, stressing fast diagnostics and ELN 2022 risk stratification. FLT3 mutations guide therapy; venetoclax+azacitidine boosts elderly outcomes. CPX-351 benefits high-risk patients over 60. MRD testing is key for treatment and transplant decisions, especially in youth.
Course Content
Credits
- AMA PRA Category 1 Credit™Non-CME
Course Details
- Duration
- 0.00 hour
- Released
- Jul 31, 2025
- Last Review
- Jul 31, 2025
- Expires
- Jul 31, 2026
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
Faculty & Disclosure
Faculty
Hugo F. Fernandez, MD
Accreditation
NA
-1769197262927.webp&w=3840&q=75)
-1769197177699.webp&w=3840&q=75)